Streetbeat News

CMPS

COMPASS Pathways plc

https://compasspathways.com

Industry

Medical - Care Facilities

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

HC Wainwright & Co. has reiterated its Buy rating for Compass Pathways, maintaining a price target of $120. This suggests confidence in the company's future performance and potential stock price increase.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 11:34 am

Canaccord Genuity maintains a Buy rating on Compass Pathways (NASDAQ:CMPS) but lowers the price target from $50 to $48.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 11:46 am

Compass Pathways shares are trading lower after the company reported worse-than-expected Q2 EPS results.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 7:54 pm

Compass Pathways reported a Q2 2024 GAAP EPS of $(0.56), missing the estimate of $(0.52).

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:33 am

HC Wainwright & Co. has reiterated its Buy rating on Compass Pathways (NASDAQ:CMPS) and maintained a $120 price target, as stated by analyst Patrick Trucchio.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 12:18 pm

PATOO, a Jamaica-based psychedelic CPG brand, has partnered with Fontana Pharmacy to introduce the first legal psilocybin-infused products to Jamaican pharmacy shelves. This move marks a significant step toward broader acceptance of psychedelic wellness products. Several publicly traded companies are at the forefront of developing and commercializing psychedelic therapies, including Compass Pathways, Atai Life Sciences, Cybin Inc., Mind Medicine, Mydecine Innovations Group, Seelos Therapeutics, and Revive Therapeutics.

Portfolio Pulse from Javier Hasse

July 31, 2024 | 12:00 pm

RBC Capital has initiated coverage on Compass Pathways (NASDAQ:CMPS) with an Outperform rating and set a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 10:42 am

A coalition of prominent researchers has urged the FDA to approve MDMA-based therapy for PTSD, highlighting its proven safety and efficacy. This comes as the FDA is set to rule on Lykos Therapeutics' MDMA therapy by August 11. The paper emphasizes the urgent need for effective PTSD treatments, citing high suicide rates among U.S. military veterans.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 6:51 pm

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Compass Pathways (NASDAQ:CMPS).

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 4:27 pm

Oregon's pioneering psilocybin industry is struggling to attract customers a year after its launch. Despite the initial excitement, the industry faces challenges such as regulatory hurdles, marketing restrictions, and competition. Some service centers have already closed, and more may follow. Entrepreneurs and facilitators are working to raise awareness and adapt to the competitive market.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 6:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.